← All trials
NCT03781739
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 18, 2017
- Primary completion
- Sep 30, 2019
- Completion date
- Sep 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mayo ClinicLead sponsor
- Mayo ClinicOverall official - principal investigator
- Mayo ClinicReponsible party - principal investigator
- American Heart AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.